Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment.
Share this article
Corporate
Score 85
Bullish
Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment
Mar 26, 2026 04:01 UTC
MRK, PFE, XLV
Medium term
Related Articles
Score 65
Netflix Executes Second Price Hike in Under 12 Months Amid Resilient Subscriber Demand
Mar 27, 15:23
Score 25
Crown Holdings appoints John M Rost as EVP and COO
Mar 27, 15:20
Score 65
Bullish
BofA Raises its Price Target on Franco-Nevada (FNV) to $311 from $280
Mar 27, 15:14
Score 35
Bullish
Citi Raises its Price Target on The New York Times (NYT) to $94
Mar 27, 15:13
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.